Tags

Type your tag names separated by a space and hit enter

Role of posterior sub-tenon triamcinolone acetonide in patients of refractory macular oedema.
J Pak Med Assoc 2016; 66(12):1602-1605JP

Abstract

OBJECTIVE

To evaluate the results of posterior sub-tenon triamcinolone acetonide in patients of refractory macular oedema suffering with retinal vascular disorders.

METHODS

This quasi-experimental study was conducted at Layton Rahmatulla Benevolent Trust, Lahore, Pakistan, from October 2014 to March 2015, and comprised eyes of patients with refractory macular oedema. The central macular thickness of all patients was determined with ocular coherence tomography before giving injection of 40mg/ml posterior sub-tenon triamcinolone acetonide. After the injection, central macular thickness of each eye was measured in follow-ups at 1st week, 1st month and 2nd month with ocular coherence tomography.

RESULTS

Of the 40 participants, 26(65%) were men and 14(35%) women. The mean age was 61.80±7.20 years. The mean central macular thickness before injection was 488.70±34.93, while it was 337.60±146 after 1st week of injection, 420.60 ± 76.13 after 1st month and 477.98±72.30 after two months. Comparisons of central macular thickness at various follow-ups showed a significant difference from the baseline to the last follow-up (p<0.001). Moreover, 4(14%) subjects showed consistent improvement in central macular thickness.

CONCLUSIONS

Posterior sub-tenon triamcinolone acetonide can be considered a short-term treatment option in cases of refractory macular oedema.

Authors+Show Affiliations

Vitreoretina, LRBT Eye Hospital, Lahore, Pakistan.Vitreoretina, LRBT Eye Hospital, Lahore, Pakistan.Vitreoretina, LRBT Eye Hospital, Lahore, Pakistan.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

28179698

Citation

Ibraheem, Rana Fahad, et al. "Role of Posterior Sub-tenon Triamcinolone Acetonide in Patients of Refractory Macular Oedema." JPMA. the Journal of the Pakistan Medical Association, vol. 66, no. 12, 2016, pp. 1602-1605.
Ibraheem RF, Iqbal W, Fawad-ur-Rehman. Role of posterior sub-tenon triamcinolone acetonide in patients of refractory macular oedema. J Pak Med Assoc. 2016;66(12):1602-1605.
Ibraheem, R. F., & Iqbal, W. (2016). Role of posterior sub-tenon triamcinolone acetonide in patients of refractory macular oedema. JPMA. the Journal of the Pakistan Medical Association, 66(12), pp. 1602-1605.
Ibraheem RF, Iqbal W, Fawad-ur-Rehman. Role of Posterior Sub-tenon Triamcinolone Acetonide in Patients of Refractory Macular Oedema. J Pak Med Assoc. 2016;66(12):1602-1605. PubMed PMID: 28179698.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Role of posterior sub-tenon triamcinolone acetonide in patients of refractory macular oedema. AU - Ibraheem,Rana Fahad, AU - Iqbal,Waseem, AU - ,, PY - 2017/2/10/entrez PY - 2017/2/10/pubmed PY - 2018/8/22/medline KW - Posterior sub-tenon (PST), Triamcinolone acetonide(TA), Central macular thickness(CMT), Ocular coherence tomography(OCT). SP - 1602 EP - 1605 JF - JPMA. The Journal of the Pakistan Medical Association JO - J Pak Med Assoc VL - 66 IS - 12 N2 - OBJECTIVE: To evaluate the results of posterior sub-tenon triamcinolone acetonide in patients of refractory macular oedema suffering with retinal vascular disorders. METHODS: This quasi-experimental study was conducted at Layton Rahmatulla Benevolent Trust, Lahore, Pakistan, from October 2014 to March 2015, and comprised eyes of patients with refractory macular oedema. The central macular thickness of all patients was determined with ocular coherence tomography before giving injection of 40mg/ml posterior sub-tenon triamcinolone acetonide. After the injection, central macular thickness of each eye was measured in follow-ups at 1st week, 1st month and 2nd month with ocular coherence tomography. RESULTS: Of the 40 participants, 26(65%) were men and 14(35%) women. The mean age was 61.80±7.20 years. The mean central macular thickness before injection was 488.70±34.93, while it was 337.60±146 after 1st week of injection, 420.60 ± 76.13 after 1st month and 477.98±72.30 after two months. Comparisons of central macular thickness at various follow-ups showed a significant difference from the baseline to the last follow-up (p<0.001). Moreover, 4(14%) subjects showed consistent improvement in central macular thickness. CONCLUSIONS: Posterior sub-tenon triamcinolone acetonide can be considered a short-term treatment option in cases of refractory macular oedema. SN - 0030-9982 UR - https://www.unboundmedicine.com/medline/citation/28179698/Role_of_posterior_sub_tenon_triamcinolone_acetonide_in_patients_of_refractory_macular_oedema_ L2 - http://jpma.org.pk/full_article-text.php?article_id=8011 DB - PRIME DP - Unbound Medicine ER -